Datametrex AI (TSXV: DM) continues to deliver on its healthcare operation as it pertains to testing for COVID-19. The company this morning announced that it has entered into arrangements to provide testing services for two new feature-length films.
Testing for the two new Hollywood films is set to take place in Montreal, with minimal additional details provided on the matter. Despite restrictions reducing in many jurisdictions across North America, COVID is said to remain as an active concern for the film production industry, especially as the Delta variant continues to spread rapidly.
The company currently offers its testing services for film crews in Vancouver, Montreal, and Toronto, with its services still in demand as a means of reducing potential cluster outbreaks of infection.
“The COVID-19 testing market in Montreal and across our network is an important business segment for Datametrex and we look to remain steadfast is supporting the film industry with COVID testing and now with the Delta variant of the virus now the dominant variant worldwide, it is right time to continue testing protocols to keep everyone working and continuing to stay healthy.”Marshall Gunter, CEO
The announcement follows the recent filing of the firms second quarter financial results, wherein the company recorded revenues of $10.4 million and positive net income.
Datametrex AI last traded at $0.18 on the TSX Venture.
FULL DISCLOSURE: DataMetrex AI Limited is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover DataMetrex AI Limited on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.